Case Overview

A patent infringement action targeting one of the medical device industry’s most ambitious surgical robotics platforms concluded quietly but decisively in the Eastern District of Texas. Cicas IP LLC v. Ethicon, Inc. et al. (Case No. 2:23-cv-00293) ended on March 5, 2024, with a joint dismissal with prejudice — the hallmark signature of a confidential settlement — just 257 days after filing.

At stake was U.S. Patent No. US6850794B2, asserted against Johnson & Johnson’s constellation of medical subsidiaries, including Ethicon, Inc., Ethicon US LLC, Ethicon SARL, Auris Health, Inc., Medical Device Business Services, Inc., and J&J itself. The accused product, Auris Health’s Monarch Platform — a robotic bronchoscopy system — represents a high-value commercial asset in the rapidly expanding surgical robotics market.

For patent attorneys, IP professionals, and R&D leaders operating in the medical device and surgical robotics space, this case offers important signals about patent assertion strategy, venue selection, and the growing litigation risk surrounding next-generation robotic surgical platforms.

The Parties

The Patent at Issue

U.S. Patent No. US6850794B2 (Application No. 09/957,477) sits at the intersection of medical device technology and robotic system control — a field experiencing explosive growth and corresponding patent litigation activity. While the specific claim language was not disclosed in the public record excerpted here, patents in this classification typically cover signal processing, catheter navigation, imaging integration, or robotic motion control — all technically relevant to bronchoscopic robotic platforms.

The Accused Product

The Monarch Platform by Auris Health is an FDA-cleared robotic bronchoscopy system enabling physicians to navigate peripheral lung regions with enhanced precision. Its commercial significance is substantial: lung cancer diagnostics represent a multi-billion-dollar addressable market, and the Monarch Platform sits at the frontier of that opportunity. Its inclusion as the accused product elevated the commercial stakes of this dispute considerably.

Legal Representation

Plaintiff: Christopher A. Honea of Garteiser Honea PLLC (Tyler, Texas-based IP litigation boutique).

Defendants: Michael E. Jones, Paul A. Bondor, Shaun William Hassett, and Sumeet Dang of Desmarais LLP (New York) and Potter Minton PC (local Eastern District knowledge).

Litigation Timeline & Procedural History

Venue selection was deliberate and strategic. The Eastern District of Texas remains one of the most plaintiff-favorable jurisdictions in U.S. patent litigation, consistently ranking among the top districts by patent case volume. Garteiser Honea PLLC’s home-court familiarity with this venue reinforces the intentionality of filing here.

The case resolved at the first instance (district court) level, meaning no appellate proceedings, PTAB inter partes review (IPR), or ITC parallel proceedings were recorded in the available case data. The 257-day duration from filing to dismissal is relatively swift by Eastern District standards, where cases frequently extend 18–36 months through trial. This compressed timeline strongly suggests that settlement negotiations commenced early — likely before or concurrent with initial discovery obligations — and that both sides reached commercial resolution without engaging in costly claim construction proceedings or Markman hearings.

No chief judge assignment data was available in the case record.

Outcome

On March 5, 2024, the Court granted a Joint Motion to Dismiss with Prejudice (Dkt. No. 34), filed jointly by Cicas IP LLC and all named defendants. The dismissal was with prejudice, meaning Cicas IP cannot re-file the same infringement claims against these defendants on this patent. Each party was ordered to bear its own costs, expenses, and attorneys’ fees — a standard settlement provision that avoids fee-shifting litigation under 35 U.S.C. § 285.

No damages amount was publicly disclosed, consistent with confidential settlement practice. No injunctive relief was ordered.

Verdict Cause Analysis

The case was initiated as a straightforward patent infringement action. Because the matter resolved before claim construction or any substantive motion practice appears on the public docket, the merits of the infringement allegations — including validity challenges, claim scope, and doctrine of equivalents arguments — were not adjudicated publicly.

The “with prejudice” dismissal is the operative legal signal here. Unlike a dismissal without prejudice (which preserves future assertion rights), this termination extinguishes Cicas IP’s ability to re-litigate these specific claims against these defendants. This outcome pattern — NPE assertion followed by relatively rapid confidential settlement — is well-documented in Eastern District patent litigation and reflects the economics of patent licensing transactions dressed in litigation clothing.

The fee-bearing allocation (each party bears its own) further confirms mutual resolution rather than a court-imposed outcome, and it removes any basis for an “exceptional case” finding under § 285.

Legal Significance

While this case does not produce a written claim construction order or precedential ruling, it carries strategic informational value:

1. Patent US6850794B2 has now been asserted in litigation, creating a prosecution and licensing history reference point for future defendants or licensees evaluating this patent’s scope.
2. The assertion against multiple corporate affiliates simultaneously — including the parent (J&J) and operational subsidiaries — reflects an NPE strategy to maximize defendant exposure and settlement leverage.
3. The Monarch Platform’s characterization as an infringing product, even absent judicial confirmation, creates a documented assertion record that future acquirers, investors, or licensing counterparties should evaluate in due diligence.